Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Eiger BioPharmaceuticals, Inc. (EIGR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update"
07/28/2023 8-K Quarterly results
06/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Employment Terms, by and between Eiger BioPharmaceuticals, Inc. and David Apelian",
"Amended and Restated Employment Terms, by and between Eiger BioPharmaceuticals, Inc. and David Apelian"
05/11/2023 8-K Quarterly results
Docs: "Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update"
04/14/2023 8-K Quarterly results
03/16/2023 8-K Quarterly results
Docs: "Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/10/2023 8-K Quarterly results
01/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/20/2022 8-K Quarterly results
12/08/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
07/18/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Open Market Sale AgreementSM, by and between Eiger BioPharmaceuticals, Inc. and Jefferies LLC",
"Opinion of Sidley Austin LLP"
03/17/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study"
03/10/2022 8-K Quarterly results
Docs: "Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update"
01/06/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones"
12/21/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus Infection"
11/04/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Eiger BioPharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update"
08/05/2021 8-K Quarterly results
06/15/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/22/2021 8-K Quarterly results
04/09/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
01/07/2021 8-K Quarterly results
01/07/2021 8-K Quarterly results
11/23/2020 8-K Acquisition/merger/asset purchase announced
Docs: "FORM 8-K",
"Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million"
11/05/2020 8-K Quarterly results
Docs: "Recent Highlights and Upcoming Milestones"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy